New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
11:32 EDTTHOR, HTWRHeartWare falls, Thoratec rallies after Wells Fargo flips ratings
Heart pump maker HeartWare (HTWR) is sinking and its competitor, Thoratec (THOR), is climbing after Wells Fargo wrote that the high rate of strokes among patients who have used Heartware's HVAD pump is worrisome. In a trial of Heartware's HVAD pump, which is designed to draw blood from the left ventricle and propel it through an outflow graft connected to the patient's ascending aorta, 11.8% of patients who used the device developed strokes, versus just 4.3% of patients who used a similar product made by Thoratec, Wells Fargo wrote in a note to investors, citing interim data. As a result, HeartWare has placed a warning about strokes on the instructions for its HVAD pump. Wells Fargo believes that this warning may curtail sales of HeartWare's device in the U.S., and the firm downgraded the company's stock to Market Perform from Outperform in a note to investors today. Wells Fargo also upgraded Thoratec to Outperform from Market Perform, as it expects the company to benefit from reduced demand for HeartWare's solution. Moreover, Wells predicts that HeartWare will report lower than expected 2013 revenue, while Thoratec is likely to beat 2013 revenue expectations. The firm also believes there is now a greater chance that HeartWare's device will not be approved as a destination therapy. In late morning trading, HeartWare fell $4.18, or 4.67%, to $85.36, while Thoratec climbed $1.91, or 5.46%, to $36.91.
News For HTWR;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:40 EDTHTWRHeartWare price target raised to $105 from $90 at Leerink
Subscribe for More Information
February 26, 2015
07:03 EDTHTWRHeartWare reports 737 HeartWave Ventricular Assist Systems sold globally
U.S. revenue, generated through the sale of 382 units during the fourth quarter of 2014, was $41.5 million, a 60% increase from $25.9 million in the fourth quarter of 2013.
07:02 EDTHTWRHeartWare reports Q4 non-GAAP EPS (41c), consensus (59c)
Subscribe for More Information
February 23, 2015
07:28 EDTHTWRHeartWare recall should not have material impact long-term, says Canaccord
Canaccord does not believe the voluntary recall issued by HeartWare should not have any material impact on its business long-term, as the serious event rate is relatively low. The recall pertains to a previously known issue and is in effect a continuation of its 2013 corrective action, Canaccord said. The firm reiterated its Buy rating and $115 price target on HeartWare shares.
February 20, 2015
16:35 EDTHTWRHeartWare issues recall of older HeartWare clinical trial controllers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use